EMEA GRANTS PTC ORPHAN DRUG DESIGNATION

PTC Therapeutics (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced that PTC124 has been granted orphan drug status for the treatment of Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF) by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA).

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=20543020&full=1)